Skip to main content
OpenTrials
Completed

NCT Number: NCT00961038

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hanover, Lower Saxony, 30625, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with COPD, 40 to 75 years of age
  • Diagnosis of COPD
  • Airway obstruction with a post-bronchodilator Forced Expiratory Volume (FEV1) of >/=30% and </=65% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of </=70%
  • Current or ex-smokers with a smoking history of more than 10 pack-years
  • Patients must be able to produce acceptable induced sputum samples (as defined in the Study Procedure Manual)
  • Normal body weight: Body Mass Index (BMI) between 19 and 35 kg/m2

Exclusion criteria

  • Significant respiratory disease other than COPD as bronchial asthma, Cystic fibrosis or clinically evident bronchiectasis
  • More than one COPD exacerbation within 12 months and within 8 weeks prior to screening
  • total blood eosinophil count >/=600/mm3
  • Thoracotomy with pulmonary resection
  • Regularly use of daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
  • Hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder
  • Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution
  • Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
  • Concomitant use of medication which could interfere with the investigational drug. Before study drug administration a wash out period of more than 5 half lives has to be considered
  • Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with
  • fluoroquinolones
  • Oral beta-andrenergics, beta blockers
  • oral steroids
  • Methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout of long-acting theophylline prior to pre-study examination
  • Antihistamines, antileukotrienes prescribed for asthma
  • oral cromolyn sodium or oral nedocromil sodium

Treatment and study plan

Ciprofloxacin (PulmoSphere, BAYQ3939)

Drug

32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)

Placebo

Drug

Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)

Primary outcomes

  1. Vital signs

    Time frame: Within 28 days after first treatment

  2. Electrocardiogram (ECG)

    Time frame: Within 28 days after first treatment

  3. Pulmonary function test

    Time frame: Within 28 days after first treatment

  4. Pulse-oximetry

    Time frame: Within 12 days after first treatment

Secondary outcomes

  1. Ciprofloxacin concentrations in blood

    Time frame: Within 14 days after first treatment

  2. Ciprofloxacin concentrations in urine

    Time frame: Within 14 days after first treatment

  3. Ciprofloxacin concentrations in sputum

    Time frame: Within 14 days after first treatment

  4. Ciprofloxacin concentrations in mouth fluid

    Time frame: Within 7 days after first treatment

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Collaborators

  • Novartis Pharmaceuticals

Registry information

Official study title

Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphere® Inhalation Powder

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Aug 18, 2009
Registry last updated
Apr 1, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.